Genetic Mutations
155 articles
Having a genetic mutation can make all the difference in treatment choices, and even longer-term survival. Learn more about the importance of genetic testing and molecular profiling.
Frequently Asked Questions About Pancreatic Cancer
Have you or someone you love just been diagnosed with pancreatic cancer? Learn some basic facts about this disease from our FAQ.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Don’t Let Doctors Tell You Nothing’s Wrong
After a long road to diagnosis Brandon Stone learned he has a BRCA2 genetic mutation that impacts his treatment.
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how earlier detection of high-risk people is key the PRECEDE trial’s goal to increase pancreatic cancer survival rates.
A New Triple Combination for Tumors with BRCA1/2 or PALB2 Mutations
A clinical trial is comparing a two-drug combination with a three-drug combination to see which works better for genetic mutations.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
BRCA Mutations and Pancreatic Cancer
Let’s Win, the National Alliance for Hispanic Health, and the Basser Center for BRCA teamed up to present a webinar on BRCA mutations and pancreatic cancer.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.